8-K: Propanc Biopharma Secures $33,000 Convertible Note to Bolster Working Capital

Propanc Biopharma has entered into a securities purchase agreement for a $33,000 convertible note to fund general working capital.

Summary

• Propanc Biopharma has secured a $33,000 convertible note from GS Capital Partners, LLC, with a purchase price of $30,000 due to an original issue discount of $3,000.
• The note bears an 8% annual interest rate, payable in common stock, and matures on February 2, 2025.
• The note is convertible into common stock at a fixed price of $0.0017 per share, which can adjust to $0.001 per share if the stock trades below $0.0014 for more than five consecutive days.
• In the event of default, the conversion price will be the lowest trading price of the common stock for the ten days prior to the default.
• The company can prepay the note with premiums ranging from 110% to 125% of the principal plus accrued interest within the first 180 days.
• A change of control event triggers a 150% redemption of the principal plus accrued interest, or the holder can convert the note into common stock.
• The company has reserved 164,000,000 shares for conversion of the note.

Sentiment

Score: 6

Explanation: The document indicates a necessary but potentially dilutive financing event. While the funding is positive, the terms of the note, including the potential for dilution and default, temper the overall sentiment.

Positives

• The convertible note provides Propanc Biopharma with $30,000 in immediate funding for working capital.
• The conversion feature allows the investor to participate in potential upside of the company's stock.
• The prepayment option provides flexibility for the company to manage its debt.
• The company has reserved a significant number of shares for conversion, indicating preparedness for potential dilution.

Negatives

• The note carries an 8% interest rate, which increases to 24% in the event of default.
• The conversion of the note could lead to significant dilution of existing shareholders.
• The company is subject to various events of default, which could trigger immediate repayment of the note.
• The conversion price can be adjusted downwards if the stock price declines, potentially increasing dilution.

Risks

• The company's stock price could fall below $0.0014 per share, triggering a lower conversion price and increased dilution.
• Failure to meet the terms of the note could result in an event of default, leading to immediate repayment and a higher interest rate.
• The company's ability to repay the note or manage the potential dilution from conversion is dependent on its future financial performance.
• The company's stock could be delisted from the OTC markets, triggering an event of default.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes. The company is also obligated to take steps to reduce the par value of its stock or conduct a reverse split if the conversion price falls below the par value.

Industry Context

This type of financing is common for small, publicly traded companies seeking to raise capital. The terms of the note, including the conversion price and default provisions, are typical for such agreements.

Comparison to Industry Standards

• The use of convertible notes is a common method for small-cap companies to raise capital, particularly in the biotech sector where Propanc operates.
• The 8% interest rate is within the typical range for such notes, although the 24% default rate is on the higher end.
• The conversion price of $0.0017 per share, with potential adjustments, is common in situations where the stock price is low and volatile.
• The prepayment premiums are also standard, designed to compensate the investor for early repayment.
• The 150% redemption premium in the event of a sale is a common protection for investors in such notes.
• Comparable companies in the biotech sector often use similar financing methods, including convertible notes and private placements, to fund their operations and research.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The company's employees may benefit from the additional working capital.
• The company's creditors may be impacted by the new debt obligation.
• The company's suppliers may benefit from the company's improved financial position.

Next Steps

• The company needs to manage its stock price to avoid triggering a lower conversion price.
• The company must ensure compliance with the terms of the note to avoid an event of default.
• The company needs to monitor its cash flow to ensure it can meet its obligations under the note.
• The company needs to secure the listing of the conversion shares if necessary.

Key Dates

Keywords

convertible note, financing, working capital, common stock, conversion price, default, prepayment, dilution, securities purchase agreement, OTC Markets